The Relationship of Serum Uric Acid With Severity of Knee Osteoarthritis
1 other identifier
observational
150
1 country
1
Brief Summary
Osteoarthritis (OA) is the most prevalent form of arthritis. Its pathogenesis remains poorly understood. Though historically regarded as a disease of mechanical degeneration, it is now appreciated that inflammation plays an important role in OA pathogenesis (Krasnokutsky et al., 2017). The hallmark of OA is the degradation and loss of articular cartilage, although most tissues of the joint become affected, such as bone, synovium, ligaments, menisci (knee), labrum (hip), periarticular fat, and muscle (Englund, 2023).It is believed that there is a pathological link between hyperuricemia and OA Therefore, we conducted a cross-sectional study to evaluate an association between elevated SUA and radiographic OA of the knee) Bipan Shrestha, 2019 (.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Dec 2023
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
November 20, 2023
CompletedFirst Posted
Study publicly available on registry
November 28, 2023
CompletedStudy Start
First participant enrolled
December 10, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 10, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
May 10, 2024
CompletedNovember 28, 2023
November 1, 2023
5 months
November 20, 2023
November 20, 2023
Conditions
Outcome Measures
Primary Outcomes (1)
percentage of serum uric acid
detect the relationship of serum uric acid with severity of knee osteoarthritis
6 months
Study Arms (2)
cases group
hyperurecemic
control group
normal
Interventions
to detect the relaton ship of serum uric acid with sevwrity of knee osteoarthritis
Eligibility Criteria
\- Adult patient (Age\>18 years) with a complaint of knee pain.
You may qualify if:
- Adult patient (Age\>18 years) with a complaint of knee pain.
You may not qualify if:
- Any patient with a history of trauma to the knee. 2 Any patient with knee complaints as a part of autoimmune connective tissue disease.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Sohag Universitylead
Study Sites (1)
Sohag university Hospital
Sohag, Egypt
Related Publications (3)
Englund M. Osteoarthritis, part of life or a curable disease? A bird's-eye view. J Intern Med. 2023 Jun;293(6):681-693. doi: 10.1111/joim.13634. Epub 2023 Apr 2.
PMID: 37004213BACKGROUNDKrasnokutsky S, Oshinsky C, Attur M, Ma S, Zhou H, Zheng F, Chen M, Patel J, Samuels J, Pike VC, Regatte R, Bencardino J, Rybak L, Abramson S, Pillinger MH. Serum Urate Levels Predict Joint Space Narrowing in Non-Gout Patients With Medial Knee Osteoarthritis. Arthritis Rheumatol. 2017 Jun;69(6):1213-1220. doi: 10.1002/art.40069. Epub 2017 Apr 28.
PMID: 28217895BACKGROUNDPark D, Park YM, Ko SH, Hyun KS, Choi YH, Min DU, Han K, Koh HS. Association of general and central obesity, and their changes with risk of knee osteoarthritis: a nationwide population-based cohort study. Sci Rep. 2023 Mar 7;13(1):3796. doi: 10.1038/s41598-023-30727-4.
PMID: 36882508BACKGROUND
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Abdullah M Ahmed, assistant professor
CONTACT
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- resident at Physical Medicine , Rheumatology and rehabilitation department
Study Record Dates
First Submitted
November 20, 2023
First Posted
November 28, 2023
Study Start
December 10, 2023
Primary Completion
May 10, 2024
Study Completion
May 10, 2024
Last Updated
November 28, 2023
Record last verified: 2023-11